BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seipel K, Porret N, Wiedemann G, Jeker B, Bacher VU, Pabst T. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. CIMB 2022;44:1463-71. [DOI: 10.3390/cimb44040098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Iacobas DA. Molecules at Play in Cancer. CIMB 2023;45:2182-2185. [DOI: 10.3390/cimb45030140] [Reference Citation Analysis]
2 Sanoyan DA, Seipel K, Bacher U, Kronig M, Porret N, Wiedemann G, Daskalakis M, Pabst T. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide- cel) for triple-class exposed relapsed/refractory multiple myeloma patients.. [DOI: 10.21203/rs.3.rs-2496118/v1] [Reference Citation Analysis]
3 Shen Y, Liu J, Wang B, Zhang Y, Xu Y, Wang X, Jia Y, Meng X, Wang X, Fan X, He A, Zhao W. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. Curr Res Transl Med 2023;71:103378. [PMID: 36720180 DOI: 10.1016/j.retram.2023.103378] [Reference Citation Analysis]
4 Rinaldi I, Muthalib A, Edina BC, Wiyono L, Winston K. Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma. Cancers 2022;14:3507. [DOI: 10.3390/cancers14143507] [Reference Citation Analysis]